<unk>  still remains to be a global problem, since current policy techniques are not adequate enough. Most policy approaches remain to be individualized, expensive, and reactive. Biomarkers could be extremely helpful in the risk assessment of pharmaceuticals for decision making in regulations. Biomarkers could help explain if a non-target organism was exposed to a pharmaceutical and the toxicity levels of the pharmaceutical in the organism if it is present. The main action for preventing<unk>  is to incinerate unwanted pharmaceutical drugs. Burning them chemically degrades their active molecules, with few exceptions. The resulting ash can be further processed before landfilling, such as to remove and recycle any heavy metals that may be present. There are now programs in many cities that provide collection points at places including drug stores, grocery stores, and police stations. People can bring their unwanted pharmaceuticals there for safe disposal, instead of flushing them (externalizing them to the waterways) or throwing them in the trash (externalizing them to a landfill, where they can become leachate). Another aspect of<unk>  prevention is environmental law and regulation, although this faces the problems of enforcement costs, enforcement corruption and negligence (see below), and, where enforcement succeeds, increased costs of doing business. The lobbying of pros and cons is ongoing.
Drug pollution
Noise pollution
Air pollution
Toxic waste
Hazardous drugs
Hazardous waste
Waterborne diseases
Biomedical waste